Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionBanque Pictet & Cie Sa
Latest Disclosed Ownership28,550 shares
Latest Disclosed Value $ 12,748,717
Banque Pictet & Cie Sa reports 17.35% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 14, 2026 - Banque Pictet & Cie Sa filed a 13F-HR form disclosing ownership of 28,550 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $12,748,717 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 16, 2026 disclosing 24,328 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 17.35% during the quarter. The current value of the position is $12,756,996 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-14 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 28,550 4,222 17.35 12,749 15.59 0.0750
2026-01-16 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 24,328 15,470 174.64 11,029 217.93 0.0647
2025-10-21 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,858 -8,079 -47.70 3,469 -53.99 0.0202
2025-07-16 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 16,937 5,564 48.92 7,540 36.77 0.0525
2025-04-30 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,373 -670 -5.56 5,514 13.69 0.0445
2025-01-30 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,043 788 7.00 4,850 -7.36 0.0324
2024-10-21 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,255 -14,009 -55.45 5,234 -55.80 0.0397
2024-07-25 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 25,264 3,024 13.60 11,842 27.38 0.1073
2024-05-06 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 22,240 -970 -4.18 9,297 -1.56 0.0873
2024-02-09 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 23,210 -3,354 -12.63 9,444 2.23 0.0782
2023-11-27 2023-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 26,564 -1,558 -5.54 9,237 -6.66 0.1090
2023-11-02 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 26,564 -1,558 9,237 0.0949
2023-08-04 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 28,122 1,215 4.52 9,896 16.74 0.0868
2023-05-01 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 26,907 2,639 10.87 8,478 20.96 0.0822
2023-02-06 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 24,268 -22,285 -47.87 7,008 -48.00 0.0731
2022-11-10 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 46,553 -14,145 -23.30 13,479 -21.20 0.1468
2022-08-08 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 60,698 -24,898 -29.09 17,104 -23.43 0.1692
2022-05-04 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 85,596 -6,905 -7.46 22,338 9.97 0.1725
2022-02-02 2021-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 92,501 57,611 165.12 20,313 220.95 0.1504
2022-02-02 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 92,501 57,611 20,313 0.1323
2021-11-12 2021-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 34,890 980 2.89 6,329 -7.43 0.0659
2021-11-10 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 34,890 980 6,329 0.0660
2021-08-12 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 33,910 -6,762 -16.63 6,837 -21.77 0.0763
2021-05-11 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 40,672 1,456 3.71 8,740 -5.70 0.1120
2021-02-10 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 39,216 37,055 1,714.72 9,268 1,476.19 0.1260
2020-11-10 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,161 316 17.13 588 9.70 0.0089
2020-08-13 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,845 140 8.21 536 32.02 0.0090
2020-04-30 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,705 0 0.00 406 8.85 0.0084
2020-02-03 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,705 0 0.00 373 29.07 0.0065
2019-11-08 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,705 0 0.00 289 -7.67 0.0055
2019-08-07 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,705 0 0.00 313 -0.32 0.0058
2019-05-02 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,705 -560 -24.72 314 -16.27 0.0060
2019-01-31 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,265 -940 -29.33 375 -39.32 0.0077
2018-11-07 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,205 1,500 87.98 618 113.10 0.0114
2018-08-09 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,705 0 0.00 290 4.32 0.0057
2018-05-09 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,705 1,705 278 0.0059
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.